One of the main challenges in targeting HIF is the potential for adverse effects, as HIF also regulates essential physiological processes in normal tissues. Achieving specificity in targeting the HIF pathway in tumor cells without affecting normal cells remains a critical hurdle. Moreover, cancer cells may develop resistance mechanisms that bypass HIF inhibition, necessitating combination therapies to improve efficacy.
